202 related articles for article (PubMed ID: 19424414)
1. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts.
Noureddine MA; Menendez D; Campbell MR; Bandele OJ; Horvath MM; Wang X; Pittman GS; Chorley BN; Resnick MA; Bell DA
PLoS Genet; 2009 May; 5(5):e1000462. PubMed ID: 19424414
[TBL] [Abstract][Full Text] [Related]
2. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
Jordan JJ; Menendez D; Inga A; Noureddine M; Bell DA; Resnick MA
PLoS Genet; 2008 Jun; 4(6):e1000104. PubMed ID: 18714371
[TBL] [Abstract][Full Text] [Related]
3. Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements.
Bandele OJ; Wang X; Campbell MR; Pittman GS; Bell DA
Nucleic Acids Res; 2011 Jan; 39(1):178-89. PubMed ID: 20817676
[TBL] [Abstract][Full Text] [Related]
4. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis.
Horvath MM; Wang X; Resnick MA; Bell DA
PLoS Genet; 2007 Jul; 3(7):e127. PubMed ID: 17677004
[TBL] [Abstract][Full Text] [Related]
5. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.
Tomso DJ; Inga A; Menendez D; Pittman GS; Campbell MR; Storici F; Bell DA; Resnick MA
Proc Natl Acad Sci U S A; 2005 May; 102(18):6431-6. PubMed ID: 15843459
[TBL] [Abstract][Full Text] [Related]
6. Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro.
Chène P
Biochem Biophys Res Commun; 1999 Sep; 263(1):1-5. PubMed ID: 10486243
[TBL] [Abstract][Full Text] [Related]
7. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.
Resnick MA; Inga A
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9934-9. PubMed ID: 12909720
[TBL] [Abstract][Full Text] [Related]
8. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.
Liu L; Scolnick DM; Trievel RC; Zhang HB; Marmorstein R; Halazonetis TD; Berger SL
Mol Cell Biol; 1999 Feb; 19(2):1202-9. PubMed ID: 9891054
[TBL] [Abstract][Full Text] [Related]
9. Functional evolution of the p53 regulatory network through its target response elements.
Jegga AG; Inga A; Menendez D; Aronow BJ; Resnick MA
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):944-9. PubMed ID: 18187580
[TBL] [Abstract][Full Text] [Related]
10. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of DNA binding sites by mutant p53 proteins.
Thukral SK; Lu Y; Blain GC; Harvey TS; Jacobsen VL
Mol Cell Biol; 1995 Sep; 15(9):5196-202. PubMed ID: 7651437
[TBL] [Abstract][Full Text] [Related]
12. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein.
Koutsodontis G; Tentes I; Papakosta P; Moustakas A; Kardassis D
J Biol Chem; 2001 Aug; 276(31):29116-25. PubMed ID: 11384995
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the p53 core domain L1 loop.
Zupnick A; Prives C
J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
[TBL] [Abstract][Full Text] [Related]
14. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.
Buzek J; Latonen L; Kurki S; Peltonen K; Laiho M
Nucleic Acids Res; 2002 Jun; 30(11):2340-8. PubMed ID: 12034820
[TBL] [Abstract][Full Text] [Related]
15. Structure-based rescue of common tumor-derived p53 mutants.
Wieczorek AM; Waterman JL; Waterman MJ; Halazonetis TD
Nat Med; 1996 Oct; 2(10):1143-6. PubMed ID: 8837616
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions.
Goh W; Lane D; Ghadessy F
Cell Cycle; 2010 Aug; 9(15):3030-8. PubMed ID: 20714218
[TBL] [Abstract][Full Text] [Related]
17. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
[TBL] [Abstract][Full Text] [Related]
18. Lysine120 interactions with p53 response elements can allosterically direct p53 organization.
Pan Y; Nussinov R
PLoS Comput Biol; 2010 Aug; 6(8):. PubMed ID: 20700496
[TBL] [Abstract][Full Text] [Related]
19. Regression based predictor for p53 transactivation.
Gowrisankar S; Jegga AG
BMC Bioinformatics; 2009 Jul; 10():215. PubMed ID: 19602281
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
